A Multicenter, Randomized, Single-Blind, Phase II Clinical Trial and Open Label Long-term Observation Study of ADSTEM Inj. to Evaluate the Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis
Latest Information Update: 19 Mar 2024
At a glance
- Drugs Autologous stem cell therapy (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors EHL Bio
Most Recent Events
- 14 Mar 2024 Planned End Date changed from 31 May 2027 to 31 Oct 2027.
- 14 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 25 Dec 2019 Planned End Date changed from 3 Jun 2027 to 31 May 2027.